Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 1;39(5):395-406.
doi: 10.1097/HCO.0000000000001166. Epub 2024 Jul 15.

Cardiac magnetic resonance findings in cardiac amyloidosis

Aneesh Dhore-Patil  1 , Vivek Modi, El-Moatasem Gabr, Akila Bersali, Amr Darwish, Dipan Shah
Affiliations
Review

Cardiac magnetic resonance findings in cardiac amyloidosis

Aneesh Dhore-Patil et al. Curr Opin Cardiol. .

Abstract

Purpose of review: The purpose of this review is to highlight the increasing importance of cardiac magnetic resonance (CMR) imaging in diagnosing and managing cardiac amyloidosis, especially given the recent advancements in treatment options.

Recent findings: This review emphasizes the crucial role of late gadolinium enhancement (LGE) with phase-sensitive inversion recovery (PSIR) techniques in both diagnosing and predicting patient outcomes in cardiac amyloidosis. The review also explores promising new techniques for diagnosing early-stage disease, such as native T1 mapping and ECV quantification. Additionally, it delves into experimental techniques like diffusion tensor imaging, MR elastography, and spectroscopy.

Summary: This review underscores CMR as a powerful tool for diagnosing cardiac amyloidosis, assessing risk factors, and monitoring treatment response. While LGE imaging remains the current best practice for diagnosis, emerging techniques such as T1 mapping and ECV quantification offer promise for improved detection, particularly in early stages of the disease. This has significant implications for patient management as newer therapeutic options become available for cardiac amyloidosis.

PubMed Disclaimer

References

    1. Garcia-Pavia P, Rapezzi C, Eriksson U, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D iseases. Eur J Heart Fail 2021; 23:512–526.
    1. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024; 390:132–142.
    1. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379:1007–1016.
    1. Rapezzi C, Aimo A, Serenelli M, et al. Critical comparison of documents from scientific societies on cardiac amyloidosis. J Am Coll Cardiol 2022; 79:1288–1303.
    1. Yilmaz A, Bauersachs J, Bengel F, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021; 110:479–506.

MeSH terms